Your browser doesn't support javascript.
loading
Ovarian reserve in patients with spondyloarthritis: impact of biological disease-modifying anti-rheumatic drugs on fertility status.
Scrivo, Rossana; Anastasi, Emanuela; Castellani, Chiara; Conti, Fabrizio; Angeloni, Antonio; Granato, Teresa.
Afiliación
  • Scrivo R; Dipartimento di Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari, UOC Reumatologia, Sapienza University of Rome, Italy. rossana.scrivo@uniroma1.it.
  • Anastasi E; Dipartimento di Medicina Sperimentale, Sapienza University of Rome, Italy.
  • Castellani C; Dipartimento di Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari, UOC Reumatologia, Sapienza University of Rome, Italy.
  • Conti F; Dipartimento di Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari, UOC Reumatologia, Sapienza University of Rome, Italy.
  • Angeloni A; Dipartimento di Medicina Sperimentale, Sapienza University of Rome, Italy.
  • Granato T; Istituto di Biologia e Patologia Molecolari, Consiglio Nazionale delle Ricerche (CNR-IBPM), Rome, Italy.
Clin Exp Rheumatol ; 40(9): 1738-1743, 2022 Sep.
Article en En | MEDLINE | ID: mdl-35349403
OBJECTIVES: Women of childbearing age may be affected by psoriatic arthritis (PsA) and ankylosing spondylitis (AS). The aim was to assess the impact of biological agents (bDMARDs) on the fertility of women with PsA and AS by evaluating the serum levels of anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH) and luteinising hormone (LH). METHODS: Consecutive female patients (18-45 years) affected by PsA or AS starting a bDMARD were retrospectively evaluated at baseline (T0) and after 8 months (T8) of treatment. At both visits, demographic and clinical data were obtained. AMH, LH, and FSH serum levels were measured. A population of fertile women matched for age, body mass index and smoking habit was included as healthy controls (HCs). RESULTS: Twenty-four patients with PsA, 20 with AS, and 44 HCs were included. The median (25th-75th percentile) levels of AMH in patients were 0.74 ng/ml (0.29-2) at baseline and 0.71 ng/ml (0.19-1.9) (p=n.s.) at T8. The median levels of AMH in HCs were 1.56 ng/ml (0.37-2.90), with no difference compared to patients. No correlation was found between the serum AMH levels and the indexes of disease activity for both PsA and AS. No differences were found in the serum levels of FSH and LH before and after treatment with bDMARDs. CONCLUSIONS: Our results support the use of bDMARDs in female patients with SpA. AMH levels were not influenced by bDMARDs nor by disease activity. AMH could be useful to assess the quantitative aspect of ovarian reserve in female SpA patients.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Artritis Psoriásica / Antirreumáticos / Espondiloartritis / Reserva Ovárica Tipo de estudio: Observational_studies Límite: Female / Humans Idioma: En Revista: Clin Exp Rheumatol Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Italia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Artritis Psoriásica / Antirreumáticos / Espondiloartritis / Reserva Ovárica Tipo de estudio: Observational_studies Límite: Female / Humans Idioma: En Revista: Clin Exp Rheumatol Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Italia